Peptides are something entirely different: short chains of amino acids joined by peptide bonds
In terms of pharmacokinetics, GLP-1 RAs can be classified as either short-acting or long-acting
Daily dietary selenium intake in a high selenium area of enshi, China
As expected, the genotypic profile of the 224 HIV-coinfected patients in this series, with higher rates of genotypes 1a, 3 and 4 and lower rates of genotypes 1b and 2, is similar to the ones found in other cohorts of HIV-coinfected patients in Spain,31,32 in whom IDU was also the most prevalent source of infection
Key Highlights: Primary endpoint met: ~1.72.0% A1C reduction at 40 weeks vs ~0.8% placebo Significant weight loss: ~1517% reduction vs ~2.5% placebo Sustained efficacy: No weight-loss plateau observed over study duration Triple mechanism: Targets GLP-1, GIP & glucagon receptors for amplified metabolic effects Convenient dosing: Once-weekly injectable therapy Why It Matters: Beyond GLP-1: Signals the shift to multi-hormone incretin therapies Dual efficacy: Combines deep A1C reduction + substantial weight loss Competitive edge: Strengthens Lillys position vs semaglutide & tirzepatide Holistic impact: Potential to improve broader cardiometabolic outcomes Key Takeaway: Retatrutide is emerging as a potential best-in-class metabolic therapy, combining powerful glucose lowering with significant weight loss
